Test Price
2,800 AED✅ Home Collection Available
AMN Gene Megaloblastic Anemia Type 1 NGS Genetic Test – Dubai & UAE | 2,800 AED | Molecular Confirmation of Imerslund-Gräsbeck Syndrome
Executive Summary & Core Metrics
- Diagnostic Accuracy Guarantee: 99.9% analytical sensitivity and specificity, confirmed by ISO 9001:2015 accredited processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM. Sample integrity is preserved through every transfer step.
- Clinical Guidance: Post-test telephonic discussion with a consultant medical geneticist to interpret your results within your personal and family context.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The AMN Gene Megaloblastic Anemia Type 1 NGS Test uses next-generation sequencing to identify pathogenic variants in the AMN gene, providing a definitive molecular diagnosis of Imerslund-Gräsbeck syndrome (hereditary cobalamin malabsorption). This comprehensive analysis covers the entire coding region and conserved splice sites, giving you a complete genetic picture of the underlying cause of your megaloblastic anemia and enabling personalised disease management.
| Feature | Our AMN NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) | Sanger Sequencing |
| Resolution | Full gene coverage (exonic + intronic boundaries) | Targeted region only; may miss deep intronic variants |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks (faster but incomplete) |
| Clinical Utility | Definitive molecular diagnosis and family planning | Limited to known familial mutation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403): “A pathogenic variant in the AMN gene provides a definitive explanation for hereditary megaloblastic anemia, but it must always be evaluated alongside serum vitamin B12, methylmalonic acid levels, and a detailed three-generation pedigree. Lifelong high-dose B12 supplementation remains the cornerstone of management; this genetic result is a powerful tool for precision care, not a substitute for clinical monitoring. I strongly recommend that every patient reviews these findings with their treating physician before making any changes to their current regimen.”
Advisory Notice – Treatment Continuity
Medication Adherence Reminder
Never discontinue prescribed vitamin B12 injections or oral supplements without explicit guidance from your physician. Abrupt cessation may lead to irreversible neurological deterioration, including peripheral neuropathy and gait disturbance.
Safety Exclusion & Emergency Indicators
Exclusion Criteria and Red Flags
- Exclusion Criteria: Active hemolysis, acute hemolytic crisis, or inability to provide informed consent (a legal guardian must consent for minors as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency Signs: Sudden severe pallor, unexplained fever, progressive paresthesia, difficulty walking, or altered mental status – seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is the AMN Gene Megaloblastic Anemia Type 1 test and why is it needed?
This next-generation sequencing test scans the entire coding region of the AMN gene for pathogenic variants that cause hereditary megaloblastic anemia type 1 (Imerslund-Gräsbeck syndrome). The analysis confirms a congenital vitamin B12 malabsorption disorder, differentiates it from acquired pernicious anemia, and enables cascade screening of at-risk family members. Early molecular diagnosis allows for timely intervention and prevents long-term neurological complications.
2. Why is pre-test genetic counseling mandatory?
Genetic counseling maps your family history through a detailed pedigree chart, revealing autosomal recessive inheritance patterns and estimating recurrence risk for future pregnancies. This session documents affected relatives, explains the implications of possible results, and ensures truly informed consent as required by UAE medical regulations (Federal Decree-Law No. 4 of 2016 on Medical Liability). The process empowers you to make educated decisions about testing and subsequent care.
3. How is the sample collected and when can I expect results?
A certified phlebotomist collects a peripheral whole blood sample at your home or office using a temperature-controlled cold-chain transport system. Our mobile team operates daily from 8 AM to 11 PM. After DNA extraction and NGS analysis, a consultant medical geneticist interprets the findings and issues a comprehensive report that classifies any detected variant and explains its clinical significance. Results are delivered within 3 to 4 weeks.
4. What does a positive AMN variant mean for my family?
A positive finding confirms that each biological sibling has a 25% chance of being affected (autosomal recessive inheritance). Carriers (heterozygotes) are generally healthy but may have slightly lower B12 levels. We recommend genetic counseling for all first-degree relatives to discuss carrier testing, early surveillance, and reproductive planning options.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, access-controlled, and processed solely for the purpose of clinical diagnosis. Our laboratory adheres to stringent standards under DHA Facility License Number 1143, ISO 9001:2015 certified, guaranteeing international benchmarks in quality and data security.
Clinical & Logistical Metadata
| Test Name | AMN Gene Megaloblastic Anemia Type 1 NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – Full gene coverage including exonic and intronic boundary regions |
| ICD-10-CM Code | D51.1, E53.8 |
| LOINC Code | 93371-3 |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians